BC Week In Review | May 25, 2015
Company News

Antisense Therapeutics, Cortendo deal

Antisense granted Cortendo exclusive rights to develop and commercialize ATL1103 for endocrinology indications. Antisense will receive $5 million up front and is eligible for up to $105 million in development and commercialization milestones, plus royalties....
BC Week In Review | Sep 8, 2014
Clinical News

ATL1103: Additional Phase II data

An open-label, European and Australian Phase II trial in 26 acromegalic patients showed that 200 mg ATL1103 given 3 times in week 1 followed by twice-weekly 200 mg ATL1103 for 12 weeks met the primary...
BioCentury | Sep 8, 2014

Highlights of weekly biotech stock moves

Regulatory milestones Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) gained $2.63 (11%) to $26.61 on Tuesday after FDA granted breakthrough therapy designation to Nuplazid pimavanserin to treat Parkinson's disease psychosis. The compound has completed a Phase III trial...
BC Extra | Sep 4, 2014
Clinical News

Antisense reports acromegaly data

Antisense Therapeutics Ltd. (ASX:ANP) said 200 mg of ATL1103 twice-weekly met the primary endpoint in a 26-patient, open-label Phase II trial to treat acromegaly. That dosage reduced serum insulin-like growth factor-1 ( IGF-1 ) levels by 26%...
BC Week In Review | Mar 31, 2014
Clinical News

ATL1103: Completed Phase II enrollment

Antisense completed enrollment of 24 acromegalic patients in an open-label, European and Australian Phase II trial evaluating 3 doses of 200 mg ATL1103 in the first week of treatment, followed by once- or twice-weekly 200...
BC Week In Review | Jan 27, 2014
Clinical News

ATL1103: Interim Phase II data

Interim data from 8 patients in an open-label, European and Australian Phase II trial showed that once- or twice-weekly 200 mg subcutaneous ATL1103 was well tolerated with no treatment-related serious adverse events reported. ATL1103 reduced...
BC Week In Review | Jul 1, 2013
Clinical News

Antisense Therapeutics, Isis Pharmaceuticals preclinical data

In mice, ATL1103 for 3 weeks suppressed growth hormone receptor RNA expression and significantly reduced downstream insulin-like growth factor-1 ( IGF-1 ) RNA expression in the liver vs. Somavert pegvisomant and octreotide. Additionally, ATL1103 plus Somavert led...
BC Week In Review | Mar 1, 2004
Clinical News

Antisense preclinical data

ANP said that in mice, ATL1103 inhibited GH activity and reduced levels of insulin-like growth factor-1 ( IGF-1 ). Antisense Therapeutics Ltd. (ASX:ANP), Melbourne, Australia   Product: ATL1103 antisense inhibitor of growth hormone (GH) receptor  ...
Items per page:
1 - 8 of 8